MAP1LC3B and ovarian carcinoma: Treatment of ovarian cancer cells with cisplatin showed a significant decrease expression of LC3B in the miR-204 mimic group (Fig. 3e) and increased expression of LC3B in the miR-204 inhibitor group (Fig. 3f).